Nanobiotix, TJU partner on preclinical research program
PARIS—Nanobiotix and Thomas Jefferson University recently announced a research collaboration aimed at accelerating NBTXR3, Nanobiotix's lead compound, in the United States. Per the terms of the agreement, Nanobiotix will fund a two-year preclinical research program, directed by Dr. Bo Lu, a professor in Department of Radiation Oncology at Jefferson and director of the department's Division of Molecular Radiation Biology. The program will study the therapeutic efficacy of NBTXR3, a nanoparticle intended to increase the local destruction of tumor masses during radiotherapy.
"Jefferson is a leader in the field of radiation oncology, and Bo Lu is internationally renowned for his work in clinical and translational radiation oncology. Therefore, we are very much looking forward to the results of this collaboration," Dr. Laurent Levy, CEO and co-founder of Nanobiotix, said in a press release.